公开(公告)号：US20230017330A1

公开(公告)日：2023-01-19

申请号：US17779826

申请日：2020-11-26

Applicant: NOVMETAPHARMA CO., LTD.

Inventor： Keun Gyu PARK ,  In Kyu LEE ,  Sung Jin CHO ,  Yeon Kyung CHOI ,  Mi Jin KIM ,  Jung Wook CHIN ,  Yong Hyun JEON ,  Jin A KIM ,  Dong Su KIM ,  Hoe Yune JUNG

IPC: A61K31/495 ,  C07K16/28 ,  C12N15/115 ,  A61K31/7105 ,  A61K31/44 ,  A61P35/00 ,  G01N33/574 ,  G01N33/68

Abstract: The present invention relates to a pharmaceutical composition for inhibiting the resistance of liver cancer to sorafenib and enhancing an anticancer effect, comprising an Estrogen-related receptor γ (ERRγ) inhibitor as an active ingredient. The present invention can be effectively used as a pharmaceutical composition for treating sorafenib-resistant advanced liver cancer.